Delcath Systems (NASDAQ:DCTH) Cut to Hold at Wall Street Zen

Delcath Systems (NASDAQ:DCTH - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

A number of other brokerages have also recently commented on DCTH. Stephens reiterated an "overweight" rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Monday, June 23rd. HC Wainwright reiterated a "buy" rating and issued a $29.00 target price (up from $24.00) on shares of Delcath Systems in a research note on Friday, May 23rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Delcath Systems presently has an average rating of "Moderate Buy" and a consensus price target of $24.00.

Delcath Systems Stock Performance

Shares of NASDAQ DCTH opened at $12.73 on Friday. The stock has a 50 day moving average price of $14.75 and a 200 day moving average price of $13.79. Delcath Systems has a 52 week low of $7.17 and a 52 week high of $18.23. The stock has a market capitalization of $443.21 million, a PE ratio of -25.45 and a beta of 0.87.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.07). The company had revenue of $19.80 million during the quarter, compared to analyst estimates of $16.83 million. Delcath Systems had a negative net margin of 26.38% and a negative return on equity of 29.44%. As a group, research analysts forecast that Delcath Systems will post -0.79 EPS for the current year.

Institutional Trading of Delcath Systems

A number of hedge funds have recently modified their holdings of DCTH. Palisades Investment Partners LLC lifted its position in Delcath Systems by 1.0% during the first quarter. Palisades Investment Partners LLC now owns 171,084 shares of the company's stock worth $2,178,000 after acquiring an additional 1,757 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Delcath Systems by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 117,620 shares of the company's stock worth $1,497,000 after purchasing an additional 2,437 shares during the last quarter. Quarry LP acquired a new stake in Delcath Systems during the 4th quarter worth approximately $34,000. OMERS ADMINISTRATION Corp lifted its holdings in Delcath Systems by 7.5% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 51,600 shares of the company's stock worth $657,000 after purchasing an additional 3,600 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Delcath Systems during the 4th quarter worth approximately $66,000. Institutional investors and hedge funds own 61.12% of the company's stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.